Fig. 2

Expression of COX-2 in the cerebral cortex by IHC: [a] Group 1 (non-infected group); [b] Group 2 (infected non-treated group); [c] Group 3 (albendazole therapy group); [d] Group 4 (curcumin therapy group); [e] Group 5 (dual curcumin and albendazole therapy group). Strong positive COX-2 immune-reactivity in the brain tissue of infected non-treated mice and moderate immune-reactivity in the albendazole and curcumin-treated groups can be observed. Weak COX-2 expression is noticed in the combined dual curcumin and albendazole therapy group; scale bar 50 μm. (f) Area percentage of COX-2 immunohistochemical expression in the different study groups; a: Significant versus negative control, b: Significant versus positive control, c: Significant versus curcumin group, d: Significant versus Albendazole group at P < 0.05 using Tukey Kramer post-Hoc comparison test